Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes  by unknown
Abstracts
Gregory L. Moneta, MD, Section EditorCardiovascular Effects of Intensive Lifestyle Intervention in Type 2
Diabetes
The Look AHEAD Research Group. N Engl J Med 2013;369:145-54.
Conclusion: Intensive lifestyle intervention focusing on weight loss
does not reduce the rate of cardiovascular events in overweight or obese
adults with type 2 diabetes.
Summary: There are numerous beneﬁts to weight loss. They include
glycemic control, control of risk factors for cardiovascular disease, improved
quality of life, and a decrease in obesity-related coexisting diseases. For these
reasons and others, weight loss is almost universally recommended for over-
weight or obese patients with type 2 diabetes (Clinical Practice Recommen-
dations, American Diabetes Association, 2013). However, although it seems
intuitive that weight loss would reduce risk of cardiovascular morbidity and
mortality in patients with type 2 diabetes, it is actually unknown whether
this is true. A Swedish study showed reduced rates of cardiovascular events
in patients with type 2 diabetes who underwent bariatric surgery (Romeo S
et al, Diabetes Care 2012;35:2613-7). However, the study was not random-
ized, and certainly, results achieved through surgery cannot be generalized
to other methods of weight loss. The authors therefore examine the critical
question: Would intensive lifestyle intervention to achieve weight loss
through caloric restriction and increased physical activity decrease cardiovas-
cular morbidity and mortality among overweight or obese patients with type
2 diabetes? In this study, conducted in 16 centers in the United States, 5145
overweight or obese patients with type 2 diabetes were randomly assigned
to participate in an intensive lifestyle intervention that promoted weight
loss through decreased caloric intake and increased physical activity, the
intervention group, or receive diabetes support and education only, the
control group. The primary outcome was a composite of death from cardio-
vascular causes, nonfatal myocardial infarction, nonfatal stroke, or hospital-
ization for angina occurring over a maximum follow-up of 13.5 years. At
a median follow-up of 9.6 years, the trial was stopped early based on analysis
of futility. Weight loss was greater in the intervention group than the control
group throughout the study (8.6% vs 0.7% at 1 year; 6% vs 3.5% at study
end). The intensive lifestyle intervention also produced greater reductions
in glycated hemoglobin and greater initial improvements in ﬁtness and in
all cardiovascular risk factors except for low-density lipoprotein cholesterol
levels. The primary outcome occurred in 403 patients in the intervention
group and in 418 in the control group (1.83 and 1.92 events/100
person-years, respectively; hazard ratio for the intervention group, 0.95;
95% conﬁdence interval, 0.83-1.09; P ¼ .51).
Comment: The authors point out that the study is not entirely nega-
tive. Although intensive lifestyle intervention compared with diabetes
support did not reduce the risk of cardiovascular morbidity and mortality,
there were other beneﬁts attributable to the intervention in the intervention
group. These included clinically meaningful improvements in glycemic
control, with a lesser percentage of patients requiring insulin treatment,
along with reductions in urinary incontinence, sleep apnea, and depression.
There were also improvements in quality of life, physical functioning, and
mobility. Although it is unfortunate that weight loss itself mediated through
lifestyle intervention does not affect cardiovascular morbidity and mortality
in type 2 diabetic patients, weight loss should still be recommended for such
patients because of a myriad of other associated health beneﬁts.
Clopidogrel with Aspirin in Acute Minor Stroke or Transient Ischemic
Attack
Wang Y., Wang Y., Zhao X., et al; and the CHANCE Investigators. N Engl
J Med 2013;369:11-9.
Conclusion: In patients with transient ischemic attack (TIA) or minor
stroke treated #24 hours after onset of symptoms, the combination of
aspirin and clopidogrel is superior to aspirin alone in reducing stroke risk
in the ﬁrst 90 days. The combination does not increase the risk of
hemorrhage.
Summary: After a TIA or a minor stroke, the risk for subsequent
stroke is high. Approximately 10% to 20% of such patients will have a stroke
#3 months after the index event, and most of these strokes will occur within
the ﬁrst 2 days (Kleindorfer D et al, Stroke 2005;36:720-3; and Coull AJ et
al, BMJ 2004:328:326). Aspirin has been shown to have a modest effect for1140secondary stroke prevention. However, aspirin is the only antiplatelet agent
that has been studied in the acute phase of stroke. Large-scale trials of
secondary prevention of ischemic events after stroke have not shown
a beneﬁt of the combination of clopidogrel and aspirin (Bhatt DL et al,
N Engl J Med 2006;354:1706-17; and Diener HC et al, Lancet
2004:364:331-7). Limitations to these studies, however, are that they did
not study the early high-risk period after stroke, included some patients
with moderate stroke severity, and had few, if any, patients with TIA.
This trial, the Clopidogrel in High-risk Patients with Acute Non Disabling
Cerebral Vascular Events (CHANCE), was designed to test the hypothesis
that 3 months of treatment with a combination of clopidogrel and aspirin
would reduce risk of recurrent stroke compared with aspirin alone in
patients with acute high-risk TIA or minor ischemic stroke. This was
a randomized, double-blind, placebo-controlled trial conducted at 114
centers in China, in which 5170 patients were randomly assigned#24 hours
after onset of a minor ischemic stroke or high-risk TIA to combination
therapy with clopidogrel (300-mg initial dose, followed by 75 mg/d for
90 days) and aspirin (75 mg/d for the ﬁrst 21 days) or to a placebo plus
aspirin (75 mg/d for 90 days). All patients on day 1 received open-label
aspirin at a clinician-determined dose of 75 to 300 mg. Primary outcome
was ischemic stroke or hemorrhage during 90 days of follow-up using an
intention-to-treat analysis. Cox proportional hazard models were used to
assess treatment differences, with study center as a random effect. In the clo-
pidogrel-aspirin group, stroke occurred in 8.2% of patients compared with
11.7% of patients in the aspirin-alone group (hazard ratio, 0.68; 95% conﬁ-
dence interval, 0.57-0.81; P < .001). Moderate or severe hemorrhage
occurred in seven patients (0.3%) in the clopidogrel-aspirin group and in
eight patients (0.3%) in the aspirin-alone group (P ¼ .73). Rate of hemor-
rhagic stroke was 0.3% in each group.
Comment: This study was conducted exclusively at Chinese centers.
Chinese patients have a higher incidence of large-artery intracranial athero-
sclerosis than Western populations (Wong LK et al, Int J Stroke
2006;1:158-9) and also appear to have a higher prevalence of genetic poly-
morphisms effecting clopidogrel (Rosemery J et al, Curr Clin Pharmacol
2007;2:93-109). In addition, the study excluded patients who underwent
carotid revascularization. Nevertheless, if one looks at Figure 1, plotting
the probability of survival free of stroke after the initial event, one sees
that the beneﬁt with the use of the combination of clopidogrel and aspirin
over aspirin alone occurs almost entirely within the ﬁrst few days of the
initial event. Therefore, when patients present with a minor stroke or
a TIA, it seems that early stroke recurrence, regardless of whether revascu-
larization is planned, is best prevented by early administration of a combina-
tion of aspirin and clopidogrel rather than use of aspirin alone.
Reestablishment of the Endothelial Lining by Endothelial Cell
Therapy Stabilizes Experimental Abdominal Aortic Aneurysms
Franck G., Dai J., Fifre A., et al. Circulation 2013;127:1877-87.
Conclusion: Endothelial cell (CE) seeding may be an effective
therapy to arrest abdominal aortic aneurysm (AAA) expansion.
Summary: AAA is the third leading cause of cardiovascular death.
Rupture is proportional to external diameter. There is evidence intraluminal
thrombus affects the structural and cellular composition of the AAA wall
(Kazi M et al, J Vasc Surg 2003;38:1283-92). Intraluminal thrombus in
an AAA is associated with loss of the luminal EC monolayer. ECs are known
to play a major role in maintenance of vascular integrity through complex
mechanisms controlling thrombosis, inﬂammation, and matrix coverage.
The casual relationship between aortic diameter expansion and the presence
of thrombus and the lack of EC coverage is an aspect of AAA pathology that
has not been well explored. The authors hypothesized that re-endotheliali-
zation would modulate aortic wall destruction and ultimately stabilize
AAAs. To test this hypothesis, they evaluated the effect of local seeding of
rat aortic ECs or peripheral blood-derived outgrowth ECs on AAA evolu-
tion. Rat aortic ECs (n ¼ 30) or serum-free medium (controls; n ¼ 29)
were seeded endovascularly immediately (day 0) or 14 days after surgery
in a rat AAA model. Rat aortic EC seeding prevented AAA formation and
stabilized formed AAAs at 28 days (diameter increased at day 0+28, 51% 6
6% vs 83% 6 6%; day 14+28, 4% 6 4% vs 22% 6 6% in rat aortic
EC-treated models vs controls, respectively; P < .01). The stabilizing effect
